Author:
Chin Yu-Tang,Wei Po-Li,Ho Yih,Nana André Wendindondé,Changou Chun A,Chen Yi-Ru,Yang Yu-Chen SH,Hsieh Meng-Ti,Hercbergs Aleck,Davis Paul J,Shih Ya-Jung,Lin Hung-Yun
Abstract
Thyroid hormone,l-thyroxine (T4), has been shown to promote ovarian cancer cell proliferation via a receptor on plasma membrane integrin αvβ3 and to induce the activation of ERK1/2 and expression of programmed death-ligand 1 (PD-L1) in cancer cells. In contrast, resveratrol binds to integrin αvβ3 at a discrete site and induces p53-dependent antiproliferation in malignant neoplastic cells. The mechanism of resveratrol action requires nuclear accumulation of inducible cyclooxygenase (COX)-2 and its complexation with phosphorylated ERK1/2. In this study, we examined the mechanism by which T4impairs resveratrol-induced antiproliferation in human ovarian cancer cells and found that T4inhibited resveratrol-induced nuclear accumulation of COX-2. Furthermore, T4increased expression and cytoplasmic accumulation of PD-L1, which in turn acted to retain inducible COX-2 in the cytoplasm. Knockdown ofPD-L1by small hairpin RNA (shRNA) relieved the inhibitory effect of T4on resveratrol-induced nuclear accumulation of COX-2- and COX-2/p53-dependent gene expression. Thus, T4inhibits COX-2-dependent apoptosis in ovarian cancer cells by retaining inducible COX-2 with PD-L1 in the cytoplasm. These findings provide new insights into the antagonizing effect of T4on resveratrol’s anticancer properties.
Subject
Cancer Research,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献